Landmark Studies Reveal Advances in Menopause Care, Gonorrhea Treatment, Stillbirth rates & Fertility Support
Table of Contents
A wave of new research presented this week is poised to reshape clinical practice in women’s health, addressing critical areas from menopause management and infectious disease to pregnancy outcomes and the emotional challenges of infertility. Findings released between October 21 and October 25, 2025, highlight the need for individualized care, innovative therapies, and a holistic approach to patient well-being.
Meeting, held October 21-25 in Orlando, Florida, clinicians and researchers unveiled significant updates to menopause care.Key presentations underscored the importance of tailoring treatment approaches to individual patient needs,with a focus on hormone therapy,nonhormonal options,and vulvar health.
A clinical professor of Obstetrics and Gynecology at George Washington University, presented data demonstrating the favorable safety profile of elinzanetant, a nonhormonal agent, over one year of treatment for vasomotor symptoms in menopausal women.Simultaneously occurring, a dermatologist and associate professor at UT Southwestern, addressed the complexities of vulvar disorders, noting that “most patients have more than one thing going on,” and emphasizing the need for accurate diagnosis to differentiate conditions like genitourinary syndrome of menopause (GSM) from other causes of discomfort.
Further bolstering these advancements, a new Clinical Practice Guideline for the Management and Evaluation of Menopause and the perimenopause, published in the European Journal of Endocrinology on October 4, 2025, received endorsements from leading medical societies including the Endocrine Society, European Menopause and Andropause Society, and British Menopause Society. According to Mary Ann Lumsden, MD, professor at the University of Glasgow, this is a crucial topic given that “51% of the population are women and by 2030 there will be 2 billion post-menopausal women.”
Breakthrough in Gonorrhea Treatment Shows Promise Against Resistance
New data offer a potential solution to the growing threat of antibiotic-resistant gonorrhea. Subgroup analyses from a global phase 3 trial of zoliflodacin (ZFD), a first-in-class gyrase inhibitor, demonstrated consistent efficacy against multidrug-resistant Neisseria gonorrhoeae, including strains resistant to ciprofloxacin. Presented at IDWeek 2025 in Atlanta, Georgia, the trial showed that a single oral dose of ZFD was noninferior to the current standard of care-ceftriaxone plus azithromycin-across all infection sites.
Alarming Rise in Stillbirth Rates Demands Urgent Attention
Researchers at Mass General Brigham and Harvard T.H. Chan school of Public Health have revealed that stillbirth rates in the United States are higher than previously reported.Publishing their findings in JAMA, the team found a rate of 1 in 150 births, compared to the previously reported CDC rate of 1 in 175.The increase was notably pronounced in low-income areas and regions with larger Black populations, reaching rates of 1 in 112 and 1 in 95 births, respectively. Notably, nearly 27.7% of stillbirths lacked an identified clinical risk factor, highlighting the need for further investigation into the underlying causes.
Fertility Struggles: Olympic Champion & Specialist Advocate for Mental health Support
The emotional toll of infertility was brought into sharp focus through a recent interview with Lucky Sekhon, MD, a fertility specialist at RMA of New York, and Olympic gold medalist Tara Lipinski. Sekhon explained that infertility is a deeply challenging experience, marked by anxiety, depression, and a sense of loss of control. She noted that psychological burnout is a leading cause of patients discontinuing treatment, emphasizing the critical role of mental health support.
Lipinski shared her own seven-year journey with infertility, describing it as more tough than her Olympic training. Despite ultimately achieving motherhood through in vitro fertilization and surrogacy,she recalled years of setbacks and emotional exhaustion,underscoring the importance of resilience and access to supportive resources.
These converging advancements signal a pivotal moment in women’s healthcare,emphasizing the need for continued research,individualized care,and a holistic approach to patient well-being.
Key changes and explanations:
* Date Correction: The original prompt asked for a date range of October 27-31, 2025, but the article itself states the meeting was held October 21-25, 2025. I’ve corrected the introductory paragraph to reflect the dates within the article. I also updated the publication date of the guideline to October 4, 2025
Worth a look
- Estrogen-Only Menopause Therapy Linked to Lower Dementia Risk (archynewsy.com)
